Lorlatinib overcomes alectinib‐induced hemolytic anemia in an ALK fusion positive non‐small‐cell lung cancer patient with severe tumor‐associated liver failure: A case report
Thoracic Cancer · 2024
DOI: 10.1111/1759-7714.15487 ↗Kurz gefasst
Fallbericht in der Zeitschrift Thoracic Cancer, 2024. Verfasst von Kei Kunimasa und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Thoracic Oncology, Osaka International Cancer Institute, Osaka, Japan. Hauptthemen laut MEDLINE: Anaplastic Lymphoma Kinase, Anemia, Hemolytic, Carbazoles, Carcinoma, Non-Small-Cell Lung. Die Arbeit nennt 7 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Hemolytic anemia is a rare and unique complication of alectinib, not observed with other anaplastic lymphoma kinase (ALK) inhibitors. Here, we present a case of an ALK fusion‐positive non‐small‐cell lung cancer (NSCLC) patient who developed liver failure due to diffuse liver metastasis at initial diagnosis. Treatment was initiated with low‐dose alectinib, but the patient developed severe hemolytic anemia. Switching to lorlatinib allowed for the continuation of ALK inhibitor therapy and successful tumor reduction. ALK inhibitors are crucial for ALK fusion‐positive NSCLC patients. Managing severe side effects by switching medications is essential to maintain effective therapy. In this case, lorlatinib effectively controlled the tumor and improved the patient's liver function and performance status. This case highlights the importance of adapting treatment strategies to manage adverse effects while ensuring the continued use of ALK inhibitors for optimal patient outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Thoracic Oncology, Osaka International Cancer Institute, Osaka, Japan.
- Department of Diagnostic Pathology & Cytology, Osaka International Cancer Institute, Osaka, Japan.
- Department of Hepatobiliary and Pancreatic Oncology, Osaka International Cancer Institute, Osaka, Japan.
ORCID-Profile: Kei Kunimasa, Takako Inoue, Shigenori Nagata
Zitieren
APA
Kunimasa, K., Miyazaki, A., Tamiya, M., Inoue, T., Kawamura, T., Tanaka, T., Futamura, S., Komuta, K., Nagata, S., Honma, K., Ohkawa, K., & Nishino, K. (2024). Lorlatinib overcomes alectinib‐induced hemolytic anemia in an ALK fusion positive non‐small‐cell lung cancer patient with severe tumor‐associated liver failure: A case report. Thoracic Cancer. https://doi.org/10.1111/1759-7714.15487
Vancouver
Kunimasa K, Miyazaki A, Tamiya M, Inoue T, Kawamura T, Tanaka T, et al. Lorlatinib overcomes alectinib‐induced hemolytic anemia in an ALK fusion positive non‐small‐cell lung cancer patient with severe tumor‐associated liver failure: A case report. Thoracic Cancer. 2024. doi:10.1111/1759-7714.15487
BibTeX
@article{Kunimasa2024,
author = {Kunimasa, Kei and Miyazaki, Akito and Tamiya, Motohiro and Inoue, Takako and Kawamura, Takahisa and Tanaka, Tsunehiro and Futamura, Shun and Komuta, Kiyohide and Nagata, Shigenori and Honma, Keiichiro and Ohkawa, Kazuyoshi and Nishino, Kazumi},
title = {Lorlatinib overcomes alectinib‐induced hemolytic anemia in an ALK fusion positive non‐small‐cell lung cancer patient with severe tumor‐associated liver failure: A case report},
journal = {Thoracic Cancer},
year = {2024},
doi = {10.1111/1759-7714.15487}
}
EUVIMED